Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 in Ovarian Peritoneal Carcinomatosis
NCT02017678Phase 2Withdrawn
- Start
- Jan 2014
- Primary completion
- Jan 2015
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in ovarian cancer. Planned start Jan 2014; status: withdrawn.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02017678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017678.